Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SRDX | Common Stock | Options Exercise | $119K | +5.58K | +24.44% | $21.31 | 28.4K | Nov 30, 2021 | Direct | |
transaction | SRDX | Common Stock | Sale | -$245K | -5.58K | -19.64% | $44.00 | 22.8K | Nov 30, 2021 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SRDX | Stock Option (right to buy) | Options Exercise | $0 | -5.58K | -100% | $0.00* | 0 | Nov 30, 2021 | Common Stock | 5.58K | $21.31 | Direct | F3 |
Id | Content |
---|---|
F1 | Reflects the weighted average price of 5,576 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 30, 2021 with sale prices ranging from $43.50 to $44.38 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
F2 | The amount beneficially owned includes 10,610 restricted stock units (RSUs) that vest on service-based vesting dates and 8,430 DSUs that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. |
F3 | Fully vested. |